InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Sunday, 11/15/2020 3:00:21 PM

Sunday, November 15, 2020 3:00:21 PM

Post# of 6724
Just In: $ABUS Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience(TM), The American Association for the Study of Liver Diseases Meeting

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted In the 60 mg every 4 week s multi-dose cohort...

Got this from ABUS - Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience(TM), The American Association for the Study of Liver Diseases Meeting

@whytestocks

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News